Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › midostaurin

midostaurin

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of midostaurin

7 trials tracked of midostaurin: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 18 citations.

7Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 3 Phase 2 4
  1. Phase 3 Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia. Completed · 18 cited
  2. Phase 3 A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) Completed
  3. Phase 3 Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Completed
  4. Phase 2 Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia Completed
  5. Phase 2 Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML Completed
  6. Phase 2 Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia Completed
Show 1 more trials
  1. Phase 2 A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Network Meta-Analysis Compares FLT3 Inhibitors in Acute Myeloid Leukemia
Oncology Meta-analysis
Network Meta-Analysis Compares FLT3 Inhibitors in Acute Myeloid Leukemia Three FLT3 inhibitors show promise for AML patients
This network meta-analysis of 6128 acute myeloid leukemia patients compared FLT3 inhibitors. Gilteritinib and midostaurin improved complete …
Gilteritinib and midostaurin boost remission rates; gilteritinib and quizartinib improve survival in AML.
Frontiers May 11, 2026